West Elects New Director to the Board
West Pharmaceutical Services (NYSE: WST) has appointed Janet Haugen to its Board of Directors, expanding the board to 12 members.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
West Pharmaceutical Services (NYSE: WST) has appointed Janet Haugen to its Board of Directors, expanding the board to 12 members. Haugen, 66, brings extensive financial and technological expertise from her previous role as Chief Financial Officer at Unisys , where she served for over 16 years. During her tenure, she led the company's transformation from a hardware-focused business to an IT services provider. Prior to Unisys, Haugen was a partner at Ernst & Young working with Fortune 500 companies. She currently serves on the boards of Bentley Systems, Juniper Networks, and CentralSquare Technologies. Haugen holds an Economics degree from Rutgers University and is a certified director of the National Association of Corporate Directors.
Positive
- Addition of director with extensive financial and technology expertise
- Board member with significant Fortune 500 experience
- Track record in business transformation and operational oversight
- Current board experience with multiple technology companies
Negative
- None.
Details
News Market Reaction – WST
The recorded move for WST in the trading session of this news was -0.33%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Ms. Haugen, 66, is the former Chief Financial Officer of Unisys Corporation, a role she served in for more than 16 years. During her 20-year tenure at Unisys, Ms. Haugen oversaw the business transformation from a mainframe hardware, software and maintenance company to an IT services and software provider. In addition to her core finance responsibilities, she had oversight of Unisys' corporate development, IT, procurement, facilities and legal functions.
Prior to joining Unisys, Ms. Haugen was a partner at Ernst & Young working with Fortune 500 companies serving global clients in the technology and manufacturing industries.
Ms. Haugen currently serves on the Board of Directors of Bentley Systems, Juniper Networks and CentralSquare Technologies.
Ms. Haugen earned her degree in Economics from Rutgers University. In addition, she is a certified director of the National Association of Corporate Directors (NACD).
"We are pleased to welcome Janet Haugen to West's Board of Directors," said Paolo Pucci, Lead Independent Director, West. "Janet's unique combination of technology and finance expertise makes her an invaluable addition to our Board of Directors. With her significant board experience and proven operational track record, Janet will help us continue to enhance the impact of West's role to deliver healthcare to millions of patients every day."
About West
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With 10,000 team members across 50 sites worldwide, West helps support our customers by delivering approximately 43 billion components and devices each year.
Headquartered in
All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted.
View original content to download multimedia:https://www.prnewswire.com/news-releases/west-elects-new-director-to-the-board-302328461.html
SOURCE West Pharmaceutical Services, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.